Deciphera Pharmaceuticals

Deciphera Pharmaceuticals PP&E per Employee

Delisted·Jun 10, 2024

The PP&E per Employee of Deciphera Pharmaceuticals (DCPH) as of Nov 1, 2026 is 26,301.96 USD. In the previous year, PP&E per Employee was 33,764.71 USD — a change of -22.10% (lower).

PP&E per Employee

26,301.96USD

YoY

-22.10%

Last updated:

PP&E per Employee of Deciphera Pharmaceuticals is 2022 26,301.96 USD. PP&E per Employee of Deciphera Pharmaceuticals was 2021 33,764.71 USD. It decreases by -22.10% lower compared to the previous year.

The Deciphera Pharmaceuticals PP&E per Employee history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

PP&E per Employee
Date
PP&E per Employee
Jan 1, 2015
1,517.65 USD
Jan 1, 2016
2,015.69 USD
Jan 1, 2017
3,286.27 USD
Jan 1, 2018
52,756.86 USD
Jan 1, 2019
107,807.84 USD
Jan 1, 2020
37,580.39 USD
Jan 1, 2021
33,764.71 USD
Jan 1, 2022
26,301.96 USD
The Deciphera Pharmaceuticals PP&E per Employee history
YEARPP&E per EmployeeYoY
26,301.96USD-22.10%
33,764.71USD-10.15%
37,580.39USD-65.14%
107,807.84USD+104.35%
52,756.86USD+1,505.37%
3,286.27USD+63.04%
2,015.69USD+32.82%
1,517.65USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Deciphera Pharmaceuticals Stock analysis

What does Deciphera Pharmaceuticals do? Deciphera Pharmaceuticals Inc is a US biopharmaceutical company specializing in the research, development, and marketing of innovative therapeutic solutions for cancer patients. The company was founded in 2003 and is headquartered in Waltham, Massachusetts. Deciphera follows a diversified business model based on multiple pillars. On one hand, the company conducts its own research and development activities to develop new therapy approaches for cancer patients. Deciphera focuses on the research of kinase inhibitors, which offer promising approaches in cancer therapy. On the other hand, the company pursues a licensing strategy by acquiring and further developing already developed active ingredients for cancer therapies in order to make them available to patients. For this purpose, the company collaborates with various partner companies and leading academics and experts in the field of cancer therapy. Deciphera is also engaged in international collaboration through partnerships with local partners in Asia for the research of new cancer therapy approaches. The company invests significant efforts in research and development to constantly adapt its products to the latest scientific advances. Deciphera aims to develop effective and safe therapies for cancer patients that improve their quality of life and increase their chances of survival. The company relies on the research of kinase inhibitors that specifically target certain signaling pathways in cancer cells and thereby inhibit the growth of tumor cells. The company already has a number of products in clinical trials and approval processes that show promising results and are expected to be on the market soon. One promising drug is Ripretinib, dedicated to the cancer type GIST. The goal is to offer a range of cancer medications that have significant treatment success and offer customers high chances of success. Overall, Deciphera Pharmaceuticals is a dynamic and research-oriented company that utilizes the most innovative technologies to give hope to cancer patients and improve the treatment of cancer diseases. With its broad portfolio of active ingredients and therapy approaches, its international presence, and its dedicated research and development, Deciphera Pharmaceuticals Inc. is at the forefront when it comes to innovative cancer treatment therapies. Deciphera Pharmaceuticals is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Deciphera Pharmaceuticals stock

PP&E per Employee of Deciphera Pharmaceuticals is 26,301.96 USD in 2022.

PP&E per Employee of Deciphera Pharmaceuticals changed from 33,764.71 USD to 26,301.96 USD, representing a -22.10% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of PP&E per Employee Deciphera Pharmaceuticals since 2006 – with annual values, charts, and detailed analysis.

PP&E per employee measures the physical capital intensity per worker. Higher values indicate more capital-intensive operations.

PP&E per Employee's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track PP&E per Employee's Deciphera Pharmaceuticals historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Workforce — Deciphera Pharmaceuticals

All Key Metrics — Deciphera Pharmaceuticals